Posts by Sandra Ansanay-Alex
Symbios opens a new factory in Yverdon
The 12 000 m2 facility will be ready next spring in the Y-Parc in Yverdon-les-Bains. Leader in the production of custom-made orthopedic prostheses, Symbios plans to double its turnover in five years. To compete with the American giants that dominate the orthopedic prosthesis market, Symbios has been banking on technological innovation since 1989. “We are…
Read MoreVolumina Medical Gets a CHF 500 000 Loan from FIT
Volumina Medical is an EPFL spin-off based in Biopôle Lausanne. The company develops a biogel that supports the repair of soft tissues. Volumina Medical is developing highly innovative biomaterials for regenerative medicine. Their solutions address high unmet needs for the markets of reconstructive and plastic surgery. Volumina’s first product is Adipearl, a leading innovative…
Read MoreSwitzerland sets to accept medical devices with FDA approval
The Federal Council is to adapt national laws so that, in addition to medical devices with an EU certificate / CE mark, medical devices with U.S. Food & Drug Administration (FDA) approval will now also be recognised in Switzerland. Although not an EU member state or even part of the European Economic Area, Switzerland…
Read MoreEUR 3.7 million for ONWARD and its partners from the European Innovation Council (EIC)
The European Innovation Council Grant has been awarded to ONWARD and its research partners, including EPFL, IICT-BAS, CEA-Leti-Clinatec, and CEAList. The company also received the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award. ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in…
Read MoreLimula wins the start-up Swiss Technology Award
During the Swiss Innovation Forum on 23 November 2022 in Basel, Limula won the Inventor Award. Two other companies were also awarded: Sevensense Robotics an ETH Zürich spin-off that wants to make delivery robots autonomous, got the start-up award. And Schleuniger Group got the Industry Innovation Award. Precision medicine made affordable Limula is…
Read MoreCERN, CHUV and THERYQ develop a revolutionary FLASH radiotherapy device to fight cancer
This FLASH radiotherapy device will use very high-energy electrons (VHEE) to treat cancers that are resistant to conventional treatments, with greatly reduced side effects. The device is the first of its kind. Based on CERN technology, it will be installed at CHUV when ready. This collaboration between CERN, CHUV and THERYQ is another example…
Read MoreProf. Jocelyne Bloch and Prof. Grégoire Courtine receive the BioAlps Academia Award, and Incyte the BioAlps Industry Award
The ceremony closed the BioAlps Networking Day on 24 November 2022 in Neuchâtel, in front of 250 key players of the Health Valley Region. BioAlps Academia Award 2022 As a teenager, Grégoire Courtine was a Superman fan. The hero was played at the time by Christopher Reeves. A riding accident left the famous actor…
Read MoreDentsply Sirona wins the Vaud International Business Award
The dental products world leader employs 700 people in the canton. Each fall, the Vaud International Business Award (PVEI) honors three companies located in the canton that are active internationally. Maillefer, founded in 1889 in Ballaigues, is now part of the Dentsply Sirona Group, which won in the “Foreign Company” category of…
Read MoreObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
The Swiss company expects the sale proceeds to resolve its current over-indebtedness position ObsEva SA, a biopharmaceutical company based in Geneva Switzerland, developing novel therapies for women’s health, today announced the sale of all of the Company’s rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million and future milestone payments…
Read MoreOpna Bio Raises $38M in Series A Financing
Opna Bio, an Epalinges, Switzerland and San Francisco, CA-based clinical-stage biopharmaceutical company, raised $38M in Series A funding. The round was led by Longitude Capital and Northpond Ventures, with participation from Menlo Ventures. The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse…
Read More